

June 02, 2025

To

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sir/Madam,

Sub: Investor Presentation

In continuation to our Letter dated May 29, 2025, and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we enclosed herewith the Investor's Presentation which will be made during RPG Annual Investor Conference 2025 scheduled to be held on June 03, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary

Encl: As above



hello happiness

RPG

Annual Investor Conference 2025

RPG Life Sciences

June 3, 2025



Disclaimer


This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

RPG Life Sciences: An Integrated Pharmaceutical Company

RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



Domestic Formulations (DF)

Develop, manufacture and market branded formulations in India & Nepal

International Formulations (IF)

Develop, manufacture and market oral solid dosage formulations in the generics and branded generics space

APIs

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category



Leader in Immunosuppressants



9 Therapies represented by High Equity Brands



50+ Markets Presence



































3 Manufacturing Facilities



1300+ Employees

Strong 'Textbook' brands ; ↑ Chronic and Specialty therapies

Key Therapies	DF Key Products				
Nephrology	Legacy Portfolio Immunosuppressants  Azathioprine  Mycophenolate Mofetil  Cyclosporine  Tacrolimus	Textbook Brands  Azathioprine  Spironolactone  Diphenoxylate HCl  Naproxen  Haloperidol  Disopyramide Phosphate	Specialty  Trastuzumab  Adalimumab  Becacizumab  Rituximab  Tofacitinib  Ferric Carboxymaltose  Denosumab	New Portfolio Chronic  Sacubitril+ Valsartan  Vildagliptin  Teneligliptin  Dapagliflozin  Solifenacin  Mirasart	Life Cycle Management (Existing Products)  Azathioprine 75 mg Tablets  Spironolactone 50 mg + Furosemide 25 mg Tablets  Spironolactone 50mg + Furosemide 25mg  Naproxen Sodium Tablet USP 275 mg / 550 mg  Naproxen Sodium Tablet USP 275 mg / 550 mg  Sumatriptan & Naproxen Sodium Tablets  Romilast  Tricaine
Rheumatology					
Oncology					
Pain Management					
Gastroenterology					
Neuropsychiatry					
Cardio- Diabeto					
Urology					



IF Key Products

Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline

Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzzantil, Dipsope



APIs Key Products

Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole


FY25 delivered a strong all-round performance

↑ Sales Growth	↑ EBITDA Growth	↑ Margin	↑ ROCE *
12.3%	27.3%	+ 312 bps	32.9%
↑ ROE *	↑ EPS *	↑ Volume Growth	↑ Market Capitalization
24.3%	Rs. 67.5	6.6%	+49%

* Excluding impact of exceptional items

Profit Margins: A Trajectory of y-o-y expansion continues un-interrupted

Significant upward trajectory across all margin metrics




* Excluding impact of exceptional items

Revenues, Profit, Cashflows: A strong y-o-y upward trajectory continues unabated


Rs. crores

Revenue Up by 12% vs LY




Revenue ~2x v/s FY19

PBT* up by 28% vs LY



PBT ~10X v/s FY19




Significant cash balance* (from operations)



Continue to have zero debt in FY25

* Excluding impact of exceptional items


Key Financial Ratios: A trajectory of y-o-y uptrend continues unabated



* Excluding impact of exceptional items

ROCE = (PBT + Finance Cost)/Capital Employed; ROE = PAT / Total Equity (i.e. post tax)

RPG Lifesciences Market Cap outperforming the benchmark over the past 5 Years



Continued strengthening of our balance sheet in FY25

Improvements recorded in ICRA Rating

- Long term rating reaffirmed at **A+** and outlook retained as stable
- Short term rating reaffirmed at **A1**



Factors affecting rating affirmation

- A robust capital structure and strong debt servicing indicators based on
 - Healthy cash flows
 - Company continues to remain debt-free
 - No debt-funded capital expenditure (capex)
- Steady growth in Top-line and improving operating margins
- Strong brands in the Indian Pharmaceutical Industry
- Expansion of product portfolio and geographical presence augur well for growth prospects

8 Strategic initiatives enabling our strong performance

1	Business Transformation & improving margin profile	Constant focus on implementing projects to build cost efficiencies across multiple projects which has resulted in EBITDA% moving from 23.3% in FY24 to 26.4% in FY25
2	Comprehensive Life Cycle Management of Legacy products	Naprosyn crosses Rs. 76 crores in FY25 - on its way to become first 100 crore brand; multiple engagement initiatives driving SoV, depth and breadth of Rx support
3	Foray into New Therapies and new product launches	The new rheumatology franchise grows to contribute 14% to specialty business; foray into ortho and critical care in FY25
4	Focus on cashflow generation to invest into driving next wave of growth	Significant surplus cash flow of Rs. 267 crores in FY25; opportunities to drive inorganic growth of our business being evaluated
5	Factories, R&D, Regulatory Gearing Up to support Frontend	Capex of ~ INR 140 crores to modernise plants and R&D infrastructure
6	Quality enhancement projects	Multiple projects underway for audit-based quality enhancement; TGA and EUGMP certification renewal obtained in FY25
7	All round Performance Recognition	Multiple Awards/Recognitions – Best Patent, Best CSR, Best Brand, Best Company, Best Values-in-action; Amongst Top 500 Value creators of India
8	Happiness Initiatives driving Happy Performance driven Culture	Happiness Score 88% Ranked #2 amongst RPG group companies

Continued focus on delivering environmental-friendly growth

41% carbon emission
reduction in FY25

52% reduction in hazardous
waste management in FY25



41% increase in
energy efficiency in FY25

7% reduction in water
consumption

RPGLS Journey Ahead: 7 strategic pillars of action




Portfolio development and mega-brands building

- Project underway to grow our immunosuppressant portfolio to 200+ crores
- Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio




Growing our API business

- Focus on new geographies, new launch pipeline and enhancing manufacturing productivity
- Focus on strengthening customer relationships and onboarding new high-value customers



Strong Digital Roadmap

- Multiple digital initiatives designed to streamline front-end and backend operations
- Initiatives focus on improving efficiency & compliance, reducing costs and growing topline



Mergers & Acquisitions

- M&A Framework with criteria defined - target therapies, brands
- Evaluation of multiple proposals underway to identify opportunities for growth synergy



New products across segments, new therapies

- Focused new product pipeline; lab modernization and org expansion complete
- Strategy to evaluate and expand into adjacencies in RPGLS strength therapies



State-of-art capacity plants

- 140 crores capex infused since FY22 helped build modern plant with EU/PICS/TGA, etc. approval
- Evaluation ongoing of varied opportunities for improving manufacturing productivity



Talent Development /Acquisition

- Org structure review & role/skill-gaps identification for strengthening
- Talent development and talent acquisition across all key business and support functions



hello happiness